Vol. 20/No. 9

Therapy for patients with multiple myeloma encompasses many agents and potential combinations, but truly personalizing care will require knowing how those agents interact for maximum efficacy and incorporating patient preferences for toxicity into the care plan.

Smoking and obesity rates are rising rapidly among middle school and high school students, and these trends may undo the progress made against tobacco- and obesity-related cancers in adults.

Since they were discovered nearly 30 years ago, microRNAs have emerged as novel targets for cancer diagnostics and therapeutics.

During a recent panel discussion, neuroendocrine tumor experts Simron Singh, MD, MPH, and Jonathan R. Strosberg, MD, provided insight on which patients are the best candidates for these approved treatments and how to sequence therapy to optimize outcomes.

Second-generation immuno-oncology studies hold great promise for breaking through the known barriers highlighted by earlier research against metastatic breast cancer.

Many oncology practices are learning lessons about the importance of persistence, persuasion, and creativity in getting I/O drugs to the patients who need them.

The Tice strain of BCG has emerged as a go-to drug for treating primary and recurrent bladder cancer, but in the United States and some other countries, a constellation of marketplace dynamics has reduced manufacturers of this agent to a sole producer that is unable to keep up with demand. Available supplies are being rationed, and sufficient expansion of supply could be years away.

It is critical to inquire what is wrong with hope, if it helps patients through their journey while not interfering with likely necessary end-of-life decisions when these are required to be made.